Idursulfase

Idursulfase
Clinical data
Drug classEnzyme[1]
Main usesMucopolysaccharidosis II (MPS-II)[1]
Side effectsRash, fever, headache, high blood pressure, flushing[2]
WHO AWaReUnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽
Pregnancy
category
    Typical dose0.5 mg/kg q 1 week[3]
    External links
    AHFS/Drugs.comMonograph
    Legal
    License data

    Idursulfase, sold under the brand name Elaprase, is a medication used to treat mucopolysaccharidosis II (MPS-II, Hunter syndrome).[1] It is given by gradual injection into a vein.[1] It is used long term.[3] Effects on life expectancy and quality of life is unclear.[4]

    Common side effects include rash, fever, headache, high blood pressure, and flushing.[2] Other side effects may include shortness of breath, heartburn, chest pain, and anaphylaxis.[2] It is a form of lysosomal enzyme known as iduronate-2-sulfatase and is made by recombinant DNA technology.[1]

    Idursulfase was approved for medical use in the United States in 2006 and Europe in 2007.[1][2] In the United States it costs about 475,000 USD to treat a 35 kg person for a year.[5] In the United Kingdom this amount costs £310,000.[3]

    Medical uses

    Dosage

    It is given at a dose of 0.5 mg/kg once per week.[3]

    References

    1. 1 2 3 4 5 6 7 "Idursulfase Monograph for Professionals". Drugs.com. Archived from the original on 2 December 2021. Retrieved 25 November 2021.
    2. 1 2 3 4 "Elaprase". Archived from the original on 11 December 2021. Retrieved 25 November 2021.
    3. 1 2 3 4 BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1116. ISBN 978-0857114105.
    4. ↑ "Idursulfase" (PDF). September 2009. Archived (PDF) from the original on 15 April 2021. Retrieved 25 November 2021.
    5. ↑ "Idursulfase Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 25 November 2021.
    Identifiers:
    • idursulfase at the US National Library of Medicine Medical Subject Headings (MeSH)
    This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.